Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
InChI
InChIKey=UVOIBTBFPOZKGP-UHFFFAOYSA-N
InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Propiomazine is a typical antipsychotic, blocking H1 receptors and is primarily indicated in conditions Insomnia. Propiomazine was also used under brand name largon for the relief of restlessness and apprehension, preoperatively or during surgery. In addition largon was used as an adjunct to analgesics for the relief of restlessness and apprehension during labor. But this drug was discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.drugs.com/mmx/largon.html |
Palliative | LARGON Approved UseUnknown Launch Date1960 |
||
Sources: https://www.drugs.com/mmx/largon.html |
Palliative | LARGON Approved UseUnknown Launch Date1960 |
||
| Primary | Unknown Approved UseUnknown |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.6 h |
single, oral |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
7.7 h |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
10.8 h |
single, intramuscular |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19% |
PROPIOMAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Socioeconomic determinants of psychotropic drug utilisation among elderly: a national population-based cross-sectional study. | 2010-03-09 |
|
| Are sedatives and hypnotics associated with increased suicide risk of suicide in the elderly? | 2009-06-04 |
|
| [Treatment of sleep disorders during pregnancy and breast feeding]. | 2006-11-23 |
|
| Mucosal delivery of cytotoxic therapeutic agents: response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiomer. | 2005-11 |
|
| Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents. | 2002-05-17 |
|
| Citalopram in fatal poisoning cases. | 2002-03-28 |
Patents
Sample Use Guides
Usual adult dose: Preoperative: intramuscular or intravenous: 20 to 40 mg administered in conjunction with 50 mg of meperidine. Sedation during surgery with local, nerve block, or spinal anesthesia: intramuscular or intravenous 10 to 20 mg. Analgesia adjunct, during labor: intramuscular or intravenous, 20 to 40 mg in the early stages of labor, then 20 to 40 mg of propiomazine administered in conjunction with 25 to 75 mg of meperidine when labor is definitely established. Doses may be repeated every three hours, if necessary.
Usual pediatric dose: sedation prior to surgery: preanesthetic or postoperative: children up to 27 kg: Intramuscular or intravenous, 550 mcg (0.55 mg) to 1.1 mg per kg of body; children 2 to 4 years of age: Intramuscular or intravenous, 10 mg; children 4 to 6 years of age: Intramuscular or intravenous, 15 mg; children 6 to 12 years of age: Intramuscular or intravenous, 25 mg.
insomnia: 25 to 50 mg oral
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:25:53 GMT 2025
by
admin
on
Mon Mar 31 18:25:53 GMT 2025
|
| Record UNII |
242Z0PM79Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
||
|
WHO-ATC |
N05CM06
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
||
|
WHO-VATC |
QN05CM06
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1201210
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
242Z0PM79Y
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
DB00777
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
8770
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB10110MIG
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
8491
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
88245-06-1
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
SUPERSEDED | |||
|
DTXSID1023520
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
206-646-1
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
2298
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
3275
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
C66486
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
735
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
4940
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
C084591
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
100000081378
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
m9206
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
PROPIOMAZINE
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
7284
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY | |||
|
362-29-8
Created by
admin on Mon Mar 31 18:25:53 GMT 2025 , Edited by admin on Mon Mar 31 18:25:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |